[go: up one dir, main page]

EP1590327A1 - Inhibiteurs du ccr8 - Google Patents

Inhibiteurs du ccr8

Info

Publication number
EP1590327A1
EP1590327A1 EP03808569A EP03808569A EP1590327A1 EP 1590327 A1 EP1590327 A1 EP 1590327A1 EP 03808569 A EP03808569 A EP 03808569A EP 03808569 A EP03808569 A EP 03808569A EP 1590327 A1 EP1590327 A1 EP 1590327A1
Authority
EP
European Patent Office
Prior art keywords
substituted
group
unsubstituted
methyl
aromatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03808569A
Other languages
German (de)
English (en)
Inventor
Bing Guan
Charles Minor
Mingshi Dai
Shomir Ghosh
Tracy J. Jenkins
Gang Li
Douglas F. Burdi
Robert A. Bennett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of EP1590327A1 publication Critical patent/EP1590327A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/47—Y being a hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/04—Derivatives of thiourea
    • C07C335/16—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C07D211/28—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Definitions

  • Chemoattractant cytokines or chemokines are a family of proinflammatory mediators that promote recruitment and activation of multiple lineages of leukocytes and lymphocytes. They can be released by many kinds of tissue cells after activation. Continuous release of chemokines at sites of inflammation mediates the ongoing migration of effector cells in chronic inflammation (Baggiolini, et. al, Nature 15:365 (1994)). Indeed, chemokines have been implicated in a wide range of human acute and chronic inflammatory diseases including, but not limited to, respiratory diseases such as asthma, inflammatory bowel disease, allergic disorders and certain autoimmune diseases such as rheumatoid arthritis.
  • Chemokines exert their biological activity by binding to specific G-protein receptors, which then transduce signals important for the development and trafficking of specific leukocyte subsets (Baggiolini, et. al, Nature 15:365 (1994)).
  • a number or chemokine receptors have been characterized and each are differentially expressed among leukocyte populations.
  • each chemokine binds specifically to a single receptor or to a small group of receptors.
  • the recruitment and activation of specific classes of leukocytes or lymphocytes can be modulated by agents which selectively act at one chemokine receptor and/or block the activity of a specific chemokine.
  • CCR8 is a chemokine receptor (see WO 99/065561) whose expression is primarily restricted to Th2 cells (Zingoni et al, J. Immunol. 161:547 (1998) and D'Ambrosio et al, J. Immunol 161:5111 (1998)).
  • 1-309 is a ligand for CCR8 and has shown to be chemotactic for Th2 cells in vitro (D'Ambrosio et al, J. Immunol 161:5111 (1998). CCR8 is also involved in eosinophil recruitment (see WO 99/065561). Thus, antagonists for CCR8 are expected to be useful in treating disorders mediated by Th2 and eosinophil cells, e.g., asthma.
  • naphthylsulfonamides also referred to herein as
  • naphthylene sulfonamides which are effective inhibitors of CCR8 activity.
  • most of the naphthylsulfonamides shown in the Tables in the Exemplification Section inhibit CCR8 activity with a K; less than 30 ⁇ M and many with a Kj less than 1.0 ⁇ M.
  • novel CCR8 inhibitors, phannaceutical compositions comprising these inhibitors and methods of treating inflammatory disorders with these inhibitors are disclosed herein.
  • One embodiment of the present invention is a compound (a CCR8 inhibitor) represented by Structural Formula (I):
  • X is a covalent bond, O or NR .
  • R a and R b are independently -H or a C1-C3 alkyl.
  • R 1 is a substituted or unsubstituted aromatic group or a substituted or unsubstituted non-aromatic ring or -NR ⁇ CH ⁇ m R 1 , taken together, is a substituted or unsubstituted non-aromatic heterocyclic group.
  • R 2 is -H or a C1-C3 alkyl group.
  • R 3 is -H; and R 4 is a substituted or unsubstituted aliphatic group, a substituted or unsubstituted phenyl group, a substituted or unsubstituted benzyl group, a substituted or unsubstituted phenethyl group, a substituted or unsubstituted non-aromatic ring, a substituted or unsubstituted non-aromatic bridged bicyclic group, or, R 3 and R 4 taken together with the nitrogen atom to which they are bonded are a substituted or unsubstituted nitrogen-containing non-aromatic heterocyclic group.
  • R 3 is -H and R 4 is a substituted or unsubstituted aromatic group or a substituted or unsubstituted non-aromatic ring.
  • R 5 is -H, or a C1-C3 alkyl group.
  • Ar is a substituted or unsubstituted bicyclic aromatic group comprising a substituted or unsubstituted first six membered aromatic group fused to a second substituted or unsubstituted six membered aromatic group or to a substituted or unsubstituted five or six membered non-aromatic ring.
  • substituents for Ar include alkyl, haloalkyl, halogen, cyano, nitro, hydroxy, haloalkoxy and alkoxy.
  • m is 0, 1, 2 or 3.
  • n is 1 or 2.
  • Another embodiment of the present invention method is a method of treating a subject with a CCR8 mediated condition or disease, e.g., a subject with asthma.
  • the method comprises the step of administering to the subject an effective amount of a CCR8 inhibitor disclosed herein.
  • a pharmaceutical composition comprises a pharmaceutically acceptable carrier or diluent and a CCR8 inhibitor disclosed herein.
  • the pharmaceutical compositions can be used in therapy, for example, to treat a subject with a CCR8 mediated condition or disease, for example, a subject with asthma.
  • Yet another embodiment of the present invention is the use of one of the disclosed CCR8 inhibitors for the manufacture of a medicament for treating a subject with a CCR8 mediated condition or disease.
  • the medicament comprises an effective amount of the CCR8 inhibitor.
  • the disclosed compounds are effective inhibitors of CCR8 and, as such, are expected to be useful in the treatment and prevention of diseases mediated by CCR8, particularly asthma.
  • Other diseases for which the disclosed CCR8 inhibitors are expected to be effective include, but not limited to, inflammatory diseases such as atopic dermatitis, allergic rhinitis, systemic anaphylaxis or hypersensitivity responses, drug allergies (e.g., to penicillin, cephalosporins), insect sting allergies and inflammatory dermatoses such as dermatitis, eczema, allergic contact dermatitis, urticaria, atherosclerosis, restenosis, myositis or (including polymyositis, dermatomyositis) .
  • inflammatory diseases such as atopic dermatitis, allergic rhinitis, systemic anaphylaxis or hypersensitivity responses
  • drug allergies e.g., to penicillin, cephalosporin
  • the present invention is directed to inhibitors of the chemokine receptor commonly referred to as "CCR8".
  • CCR8 is expressed on monocytes and Th2 lymphocytes and in the brain, spleen and thymus. It is the receptor for the chemokine 1-309, which is chemotactic for Th2 cells. 1-309 has also shown to be involved in esinophil recruitment.
  • the disclosed compounds can be used to inhibit CCR8 activity; to inhibit 1-309 activity and to inhibit or treat (therapeutically or prophylactically) conditions mediated by CCR8 and/or 1-309, including inflammatory disorders and allergic conditions.
  • the disclosed compounds can also be advantageously used to inhibit conditions mediated by esinophils and by monocytes, T lymphocytes and other immune system cells which express CCR8, including inflammatory disorders and allergic conditions mediated by these cells.
  • Ar in Structural Formula (I) is preferably a naphthyl or tetrahydronaphthyl group.
  • the invention is not limited to any particular substitution pattern of the amide and sulfonamide on the naphthyl or tetrahydronaphthyl group represented by Ar.
  • compounds with 1,3-, 1,4-, 1,5-, 1,6- and 1,7- substitution patterns are more specific embodiments of the invention.
  • R 10 and R 12 are provided below in the section describing suitable aromatic and aliphatic group substituents.
  • the compound is characterized by features (1); (2); (3); (4); (5); (6); (7); (8); (1) and (4); (1), (2) and (4); (1), (3) and (4); (1), (4) and (5); (1), (4), and (6); (1), (4) and (7); (1), (4) and (8); (1), (4), (7) and (8); (1), (2), (4), (7) and (8); (1), (3), (4), (7) and (8); (1), (4), (5), (7) and (8); (1), (4), (6), (7) and (8); (1), (2), (3), (4), (5), (7) and (8); (1), (2), (4), (5), (6), (7) and (8); and (1), (3), (4), (5), (6), (7) and (8).
  • the compound represented by Structural Formula (I) is characterized by all
  • the CCR8 inhibitor is represented by any one of Structural Formulas (II)-(VI):
  • the CCR8 inhibitor is represented by any one of Structural Formulas (VII)-(XI):
  • the CCR8 inhibitor is represented by any one of structural Formulas (XII)-(XVI):
  • the CCR8 inhibitor is represented by any one of structural Formulas (XVII)-(XXI):
  • the CCR8 inhibitor is represented by any one of structural Formulas (XXII)-(XXVI): (XXIII)
  • the CCR8 inhibitor is represented by any one of structural Formulas (XXVII)-(XXXI): (XXVII) (XXVIII)
  • the CCR8 inhibitor is represented by Structural Formulas (XXXII) or (XXXIII):
  • the CCR8 inhibitor is represented by structural Formulas (XXXIV) or (XXXV):
  • the CCR8 inhibitor is represented Structural Formulas (XXXVI) or (XXXVII):
  • the CCR8 inhibitor is represented by Structural Formulas (XXXVUi) or (XXXIX):
  • 1,4- and 1,5- substitution patterns e.g., Structural Formulas (III), (IV), (VIII), (IX), (XIII), (XIV), (XVIII) (XXIX), (XXIII), (XXIV), (XXVIII), (XXIX) and (XXXII)-(XXXIX)
  • 1,4-Naphthylsulfonamides and 1,4- tetrahydronaphthylsulfonamides are disclosed in the co-pending U.S. Provisional Patent Application No. 60/436,508 entitled CCR8 INHIBITORS, filed on December 23, 2002, and U.S. Utility Application, Attorney Docket No. 1855.2047-001, entitled CCR8 INHIBITORS, filed on December 22, 2003. The entire teachings of both applications are incorporated herein by reference.
  • Rings A and B in Structural Formulas (II)-(XI) and (XVII)-(XXXI) and Ring A in Structural Formulas (XII)-(XVI), (XXII)-XXVI) and (XXXII)-(XXXIX) are optionally and independently substituted at any one or more substitutable ring carbons.
  • Exemplary substituents for Rings A and B are provided hereinbelow in the section describing aromatic group substituents.
  • Preferred substituents for Rings A and B include alkyl, haloalkyl, halogen, cyano, nitro, hydroxy, haloalkoxy and alkoxy.
  • Rings A and B are unsubstituted.
  • Structural Formulas (II)-(LXXXLX) are as defined for Structural Formula (I).
  • X is preferably a covalent bond.
  • R 4 in Structural Formulas (I)-(XXXIX) is a substituted or unsubstituted non-aromatic ring. Suitable substituents for a non-aromatic ring represented by R 4 are provided hereinbelow in the section describing substituents for a non-aromatic group and in the section below describing substituents for the nitrogen atom of a non-aromatic heterocyclic group.
  • R 4 in Structural Formulas (I)- (XXXIX) is a non-aromatic ring
  • preferred values include a piperidinyl group, an N- substituted piperidinyl group, or a cyclohexyl group.
  • Suitable substituents for the nitrogen atom in a piperidinyl group represented by R 4 are provided hereinbelow in the section describing substituents on the nitrogen atom of a non-aromatic heterocyclic group.
  • Preferred substituents for the nitrogen atom in a piperidinyl group represented by R 4 include R 15 , -C(O)R 15 , -C(O)OR 15 and -C(O)- ⁇ HR 15 .
  • Other preferred substituents for the nitrogen atom in a piperidinyl group represented by R 4 include -C(O)-N(R 15 ) 2 or -C(O)CH[N(R 16 ) 2 ]R 17 .
  • R 15 is -H, a non-aromatic ring or a substituted or unsubstituted aliphatic group or a substituted or unsubstituted C7-C9 aralkyl group. Typically, however, -C(O)OR 15 is not -COOH. R 15 can also be a substituted non-aromatic ring. In addition, N(R 15 ) 2 taken together can be a substituted or unsubstituted five or six membered non-aromatic nitrogen-containing heterocyclic group.
  • Preferred substituents for a substitutable carbon of the non-aromatic ring represented by R 15 or the non-aromatic heterocyclic group represented by N(R 1S ) 2 included methyl, ethyl hydroxyethyl and iso-propyl; suitable substituents for a substitutable nitrogen of these groups include alkyl, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl and dialkylaminocarbonyl.
  • R 16 is -H or an alkyl group.
  • R 17 is -H; a C 1 -C6 alkyl group optionally substituted with -OH, -NH 2 , phenyl or phenyl substituted with -OH; indolyl; imidazolyl; or phenyl optionally substituted with -OH.
  • R 4 in Structural Formulas (I)-(XXXIX is a phenyl group, a substituted phenyl group, a benzyl group or a substituted benzyl group.
  • Suitable substituents for phenyl and benzyl groups represented by R 4 are provided hereinbelow in the section describing suitable aromatic group substituents.
  • Preferred substituents are electron donating groups such as methoxy, ethoxy, iso-propoxy, methyl, ethyl, propyl, NH 2 , NHCH 3 , N(CH 3 ) 2 , NHCH 2 CH 3 , N(CH 2 CH 3 ) 2 , N(CH 3 )(CH 2 CH 3 ), NH(CH 2 CH 2 CH 3 ), N(CH 2 CH 2 CH 3 ) 2 , N(CH 3 )(CH 2 CH 2 CH 3 ) or N(CH 2 CH 3 )(CH 2 CH 2 CH 3 ).
  • -NR 3 R 4 in Structural Formulas (I)- (XXXIX), taken together is a substituted or unsubstituted non-aromatic heterocyclic group.
  • Suitable substituents for a non-aromatic heterocyclic group represented by - NR 3 R 4 are provided hereinbelow in the section describing suitable substituents for a non-aromatic group and in the section describing suitable substituents for the nitrogen atom of a non-aromatic heterocyclic group.
  • R 1 is preferably a substituted or unsubstituted cyclohexyl group, a substituted or substituted phenyl group, a substituted or substituted benzyl group, a substituted or substituted pyridyl group or a substituted or a substituted -CH 2 -(pyridyl) group, and more preferably is an unsubstituted phenyl group, an unsubstituted benzyl group or a phenyl or benzyl group substituted with an electron donating group.
  • R 4 preferably is a piperidinyl group, an N-substituted piperidinyl group, a cyclohexyl group, a substituted cyclohexyl group, an unsubstituted phenyl group, an unsubstituted benzyl group or a phenyl or benzyl group substituted with an electron donating group or - ⁇ R 3 R 4 taken together is a nitrogen-containing non-aromatic heterocyclic ring, as described in the previous three paragraphs.
  • Preferred substituents for the nitrogen atom in the piperidinyl group represented by R 4 and recited in this paragraph include R 15 , -C(O)R 15 , -C(O)OR 15 , -C(O)-NHR ]5 , -C(O)-N(R 15 ) 2 and -C(O)CH[N(R 16 ) 2 ]R 17 .
  • a compound represented by Structural Formulas (II)-(XVI) wherein the X-(C Z)-NH group is replaced with a carbamate (-O-C(O)NH-), a thiocarbamate (-O-C(S)NH-), a urethane (NH-C(O)-NH-) or a thiourethane group (NH-C(S)-NH-).
  • Yet another preferred embodiment of the present invention is a compound represented by Structural Formulas (XL) or (XLI):
  • R 1 is cyclohexyl or phenyl, furanyl, thienyl or pyridyl optionally substituted with C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, methylenedioxy, ethylenedioxy, halogen, cyano, or nitro.
  • R 21 is methyl, ethyl 2-hydroxyethyl or iso-propyl.
  • R 21 indicates that the piperidinyl groups in Structural Formulas (XI) and (XII) are optionally substituted at up to four substitutable carbon atoms with R 21 .
  • a substitutable methylene group in the piperidinyl rings can optionally be substituted with up to two independently selected R 21 s.
  • R 22 is -H or C1-C4 alkyl or -N(R 22 ) 2 taken together is N-pyrollidinyl or N-piperidinyl, provided that R 22 is not -H when R 20 is -COOR 22 .
  • R 23 is -H, methyl or ethyl.
  • R 24 is -H, methyl, ethyl, phenyl, benzyl, 4-hydroxyphenyl or 4-hydroxybenzyl. s is 0, 1, 2, 3, or 4.
  • Also disclosed herein is a compound represented by any one of Structural Formulas (I)-(XLI) and methods of use thereof for treating a subject with a CCR8 mediated condition or disease and pharmaceutical compositions comprising the same, wherein R 1 has the value corresponding to any one of the compounds in the Tables and Examples in the Exemplification Section and the remainder of the variables are as defined above. Also disclosed herein is a compound represented by any one of structural Formulas (I)-(XLI) and methods of use thereof for treating a subject with a CCR8 mediated condition or disease and pharmaceutical compositions comprising the same, wherein R 1 has the value corresponding to any one of the compounds in the Tables and Examples in the Exemplification Section and the remainder of the variables are as defined above. Also disclosed herein is a compound represented by any one of structural Formulas (I)-(XLI) and methods of use thereof for treating a subject with a CCR8 mediated condition or disease and pharmaceutical compositions comprising the same, wherein R 1 has the value corresponding to any one of
  • aliphatic as used herein means straight-chain or branched hydrocarbons which are completely saturated or which contain one or more units of unsaturation, but which are not aromatic.
  • An aliphatic group is typically C ⁇ - 8 , more typically C ⁇ - 6 .
  • suitable aliphatic groups include substituted or unsubstituted linear or branched alkyl, alkenyl, alkynyl groups and hybrids thereof.
  • alkyl”, “alkoxy”, “hydroxyalkyl”, “alkoxyalkylene”, and “alkoxycarbonyl”, used alone or as part of a larger moiety includes both straight and branched saturated chains containing one to eight carbon atoms.
  • alkenyl and alkynyl used alone or as part of a larger moiety shall include both straight and branched chains containing two to eight carbon atoms and one or more double and/or triple bonds, respectively.
  • non-aromatic ring used alone or as part of a larger moiety, includes non-aromatic heterocyclic groups and cycloaliphatic groups.
  • haloalkyl means an alkyl group substituted with one or more halogens.
  • cycloaliphatic used alone or as part of a larger moiety, shall include cyclic C 3 -C ⁇ o hydrocarbons which are completely saturated or which contain one or more units of unsaturation, but which are not aromatic. Cycloaliphatic groups are typically C 3 - ⁇ o, more typically C 3 . 7 .
  • a "cycloalkyl” is a cyclic aliphatic group that is completely saturated.
  • non-aromatic bridged bicyclic group used alone or as part of a larger moiety, shall include bicyclic ring systems comprising from seven to fifteen ring atoms in which at least three adjacent ring atoms in the bicyclic ring system are shared by both rings.
  • the ring systems can be carbocyclic, in which all ring atoms are carbon, or heterocyclic ("bridged bicyclic non-aromatic heterocyclic groups"), in which one or more ring carbons are replaced with nitrogen, oxygen, sulfur and the like. Examples are shown below:
  • Suitable substituents for substitutable carbon atoms of a non-aromatic bridged bicyclic group are as provided below for non-aromatic heterocyclic groups.
  • Suitable substituents for substitutable nitrogen atoms of a non-aromatic bridged bicyclic group are as provided below for non-aromatic heterocyclic groups.
  • Alkoxy means (alkyl)-O-;
  • alkoxyalkylene means (alkyl)-O-(alkylene) such as methoxymethylene (CH 3 OCH 2 );
  • hydroxyalkyl means hydroxy substituted alkyl group;
  • alkoxy carbonyl means a carbonyl substituted with a carbonyl as in (alkyl)-O-C(O)-; and
  • aralkyl mean alkyl substituted with an aromatic group.
  • a "C1-C4 aralkyl group for example, has a C1-C4 alkyl group substituted with an aromatic group.
  • heteroatom means nitrogen, oxygen, or sulfur and includes any oxidized form of nitrogen and sulfur, and the quaternized form of any basic nitrogen.
  • nitrogen includes a substitutable nitrogen of a heterocyclic ring.
  • the nitrogen in a saturated or partially unsaturated ring having 0-3 heteroatoms selected from oxygen, sulfur or nitrogen, the nitrogen may be N (as in 3,4-dihydro- 2H-pyrrolyl), N ⁇ (as in pyrrolidinyl) or NR + (as in N-substituted pyrrolidinyl).
  • aromatic group used alone or as part of a larger moiety as in “aralkyl”, “aralkoxy”, or “aryloxyalkyl”, includes carbocyclic aromatic ring groups and heteroaryl rings groups.
  • aromatic group may be used interchangeably with the terms “aryl”, “aryl ring” or “aromatic ring”.
  • Carbocyclic aromatic ring groups have only carbon ring atoms and include monocyclic aromatic rings such as phenyl and fused polycyclic aromatic ring systems in which two or more carbocyclic aromatic rings are fused to one another.
  • Examples of carbocyclic aromatic ring groups include 1 -naphthyl, 2-naphthyl, 1-anthracyl and 2-anthracyl.
  • Carbocyclic aromatic ring is a group in which an aromatic ring is fused to one or more non-aromatic rings (aliphatic or heterocyclic), such as in an indanyl, phthalimidyl, naphthimidyl, phenantriidinyl, or tetrahydronaphthyl, where the radical or point of attachment is on the aromatic ring.
  • non-aromatic rings aliphatic or heterocyclic
  • heteroaryl used alone or as part of a larger moiety as in “heteroaralkyl” or “heteroarylalkoxy”, refers to heteroaromatic ring groups having five to fourteen members, including monocyclic heteraromatic rings and polycyclic aromatic rings in which a monocyclic aromatic ring is fused to one or more other carbocyclic or heteroaromatic aromatic rings .
  • heteroaryl groups including heteroaryl groups represented by R°, R 1 and R * , include 2-furanyl, 3-furanyl, N-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5- imidazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-oxadiazolyl, 5 -oxadiazolyl, 2- oxazolyl, 4-oxazolyl, 5-oxazolyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 2-pyridyl, 3- pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl, 5-pyrimidyl, 3 -pyridazinyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-triazolyl, 5-triazolyl, tetrazolyl, 2-thienyl, 3 -thienyl, carbazolyl,
  • heteroaryl is a group in which a heteroaryl ring is fused to one or more cycloaliphatic or non-aromatic heterocyclic groups where the radical or point of attachment is on the heteroaromatic ring.
  • heteroaryl examples include tetrahydroquinolinyl, tetrahydroisoquinolinyl, and pyrido [3, 4-d] pyrimidinyl.
  • non-aromatic heterocyclic ring used alone or as part of a larger moiety as in “hetercyclylalkyl”, refers to non-aromatic ring systems typically having five to fourteen members, preferably five to ten, in which one or more ring carbons, preferably one to four, are each replaced by a heteroatom such as N, O, or S.
  • non-aromatic heterocyclic rings examples include 3-lH-benzimidazol-2-one, 3- tetrahydrofuranyl, 2-tetrahydropyranyl, 3-tetrahydropyranyl, 4-tetrahydropyranyl, [l,3]-dioxalanyl, [l,3]-dithiolanyl, [l,3]-dioxanyl, 2-tetrahydrothiophenyl, 3- tetrahydrothiophenyl, 2-morpholinyl, 3-morpholinyl, 4-morpholinyl, 2- thiomorpholinyl, 3-thiomorpholinyl, 4-thiomorpholinyl, 1 -pyrrolidinyl, 2- pyrrolidinyl, 3-pyrorolidinyl, 1-piperazinyl, 2-piperazinyl, 1 -piperidinyl, 2- piperidinyl, 3 -piperidinyl, 4-piperidinyl, 4-thiazolidinyl
  • the CCR8 inhibitors of the present invention comprise aromatic groups, aliphatic groups and non-aromatic rings (including cycloaliphatic groups and non-aromatic heterocyclic groups) which are optionally substituted, i.e., which comprise one or more substituents.
  • Substituents can be found at one or more substitutable carbon atoms in aromatic groups, aliphatic groups and non-aromatic rings and substitutable nitrogen atoms in heteroaromatic groups and non-aromatic heterocyclic rings.
  • exemplary substituents at the carbon atoms of an aromatic group represented by R 1 are represented by R 10 ; exemplary substituents at the carbon atoms of an aliphatic group represented by R 4 are represented by R n ; and exemplary substituents at the carbon atoms of an aromatic group represented by R 4 are represented by R 12 .
  • Suitable values for the substituents represented by R 10 -R 12 and suitable substituents for the substitutable carbon atoms of Rings A and B and for other aromatic groups, aliphatic groups and non-aromatic rings (including cycloaliphatic rings and non-aromatic heterocyclic rings) that form part(s) of the disclosed CCR8 inhibitors are those which do not significantly reduce the compounds ability to antagonize the activity of CCR8 and/or which do not significantly increase toxicity to the subject.
  • Examples include -R°, -OH, -OR 0 , -O(haloalkyl), -SH, -SR°, 1,2- methylene-dioxy, 1,2-ethylenedioxy, phenyl (Ph), substituted Ph, -O(Ph), substituted -O(Ph), -CH 2 (Ph), substituted -CH 2 (Ph), -CH 2 CH 2 (Ph), substituted -CH 2 CH 2 (Ph), -CN, -NR'CO 2 R°, -NR'NR'C(O)R°, -N(R')C(O)N(R') 2 , -NR'NR'C(O)N(R') 2 , -NR'NR'CO 2 R°, -C(O)C(O)R°, -C(O)CH 2 C(O)R°, -C(O)R°, -OC(O)R°, -OC(O)N(R°) 2
  • -NO 2 -N(R') 2 , -C(O)N(R°) 2 , -NR'C(O)R°, -NR'C(O)R°, -V-N(R') 2 , -V-NR'C(O)R° and -V-C(O)N(R°) 2 are permissible values for R 10 and R n and are permissible substituents for the substitutable carbon atoms of Rings A and B and for other aromatic groups, aliphatic groups and non-aromatic rings that form part(s) of the disclosed CCR8 inhibitors; and -COOR 0 is a permissible value for R 10 and R 12 and is a permissible substituent for the substitutable carbon atoms of Rings A and
  • preferred substituents for aromatic groups, aliphatic groups and non-aromatic rings that form part(s) of the disclosed CCR8 inhibitors are alkyl, haloalkyl, halogen, cyano, nitro, hydroxy, haloalkoxy and alkoxy.
  • Amine, alkylamine and dialkyamine are also a preferred substituents for substitutable carbon atoms of an aliphatic group or a non-aromatic ring of the disclosed CCR8 inhibitors.
  • a substitutable methylene group in an aliphatic or non-aromatic ring permissably has up to two substituents.
  • the carbon atoms of aliphatic groups and non-aromatic rings e.g., a non-aromatic ring represented by R 1 , a non- aromatic heterocyclic group formed from NR 5 (CH m )R 1 , a non-aromatic ring formed from NR 3 R 4 or a non-aromatic ring represented by R 4
  • the disclosed CCR8 inhibitors are unsubstituted or substituted with an alkyl group, hydroxyalkyl group or halogen.
  • Each R* is independently selected from hydrogen, an unsubstituted aliphatic group or a substituted aliphatic group, preferably from hydrogen or an alkyl group.
  • Each R° is independently hydrogen or substituted or unsubstituted aliphatic group, a substituted or unsubstituted cycloaliphatic group, a substituted or unsubstituted non-aromatic heterocyclic group or a substituted or unsubstituted aromatic group, preferably phenyl group.
  • each R° is independently hydrogen, an alkyl group, a cycloalkyl group, a non-aromatic heterocyclic group or an aromatic group (preferably phenyl).
  • Each R' is independently R°, -CO 2 R°, -SO 2 R° or -C(O)R°.
  • V is a C1-C6 alkylene group.
  • R + is hydrogen, an aliphatic group, a substituted aliphatic group, phenyl, substituted phenyl, benzyl, substituted benzyl or an unsubstituted heteroaryl or non- aromatic heterocyclic ring.
  • R + can also be a substituted non-aromatic heterocyclic group and a substituted or unsubstituted cycloaliphatic group; or N(R*) 2 is a non- aromatic heterocyclic group.
  • Examples of substituents on the aliphatic group represented by R examples of substituents on the aliphatic, aromatic, cycloaliphatic or non-aromatic heterocyclic group represented by R° and examples of substituents on the aliphatic group, phenyl group, phenoxy group or benzyl group represented by R + include amino, alkylamino, dialkylamino, aminocarbonyl, halogen, alkyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylaminocarbonyloxy, dialkylaminocarbonyloxy, alkoxy, nitro, cyano, carboxy, alkoxycarbonyl, alkylcarbonyl, hydroxy, haloalkoxy, or haloalkyl.
  • Electron donating group is a substituent which results in a phenyl ring that has more electron density when the group is present than when it is absent. Electron donating groups have a Hammet sigma value greater than one (see, for example , C. Hansch, A. Leo and D. Hoeckman, "Exploring QSAR Hydrophobic, Electronic and Steric Constants", American Chemical Society (1995), pages 217- 32). Examples of electron donating groups include alkoxy groups, alkyl groups, amine, alkylamine and dialkylamine. Additionally, pharmaceutically acceptable salts of the compounds disclosed herein are also included in the present invention and can be used in the compositions and methods disclosed herein.
  • an acid salt of a compound containing an amine or other basic group can be obtained, by reacting the compound with a suitable organic or inorganic acid, such as hydrogen chloride, hydrogen bromide, acetic acid, perchloric acid and the like.
  • a suitable organic or inorganic acid such as hydrogen chloride, hydrogen bromide, acetic acid, perchloric acid and the like.
  • Compounds with a quaternary ammonium group also contain a counteranion such as chloride, bromide, iodide, acetate, perchlorate and the like.
  • Other examples of such salts include hydrochlorides, hydrobromides, sulfates, methanesulfonates, nitrates, maleates, acetates, citrates, fumarates, tartrates [e.g. (+)-tartrates, (-)-tartrates or mixtures thereof including racemic mixtures], succinates, benzoates and salts with amino acids such as glut
  • Salts of compounds containing a carboxylic acid or other acidic functional group can be prepared by reacting with a suitable base.
  • a suitable base which affords a pharmaceutically acceptable cation, which includes alkali metal salts (especially sodium and potassium), alkaline earth metal salts (especially calcium and magnesium), aluminum salts and ammonium salts, as well as salts made from physiologically acceptable organic bases such as trimethylamine, triethylamine, morpholine, pyridine, piperidine, picoline, dicyclohexylamine, N,N'-dibenzylethylenediamine, 2-hydroxyethylamine, bis-(2- hydroxyethyl)amine, tri-(2-hydroxyethyl)amine, procaine, dibenzylpiperidine, dehydroabietylamine, N,N'-bisdehydroabietylamine, glucamine, N-methylglucamine, collidine, quinine, quinoline, and basic amino acid
  • CCR8 inhibitors contain one or more chiral centers.
  • the presence of chiral centers in a molecule gives rise to stereoisomers.
  • enantiomers exist for every chiral center in a molecule; and a pair of diastereomers exist for every chiral center in a compound having two or more chiral centers.
  • the present invention encompasses one enantiomer of inhibitor free from the corresponding optical isomer, racemic mixture of the inhibitor and mixtures enriched in one enantiomer relative to its corresponding optical isomer.
  • the mixture contains, for example, an enantiomeric excess of at least 50%, 75%, 90%, 95% 99% or 99.5%.
  • the enantiomers of the present invention may be resolved by methods known to those skilled in the art, for example by formation of diastereoisomeric salts which may be separated, for example, by crystallization; formation of diastereoisomeric derivatives or complexes which may be separated, for example, by crystallization, gas-liquid or liquid chromatography; selective reaction of one enantiomer with an enantiomer-specific reagent, for example enzymatic esterification; or gas-liquid or liquid chromatography in a chiral environment, for example on a chiral support for example silica with a bound chiral ligand or in the presence of a chiral solvent.
  • enantiomers may be synthesized by asymmetric synthesis using optically active reagents, substrates, catalysts or solvents, or by converting one enantiomer into the other by asymmetric transformation.
  • the present invention encompasses a diastereomer free of other diastereomers, a pair of diastereomers free from other diasteromeric pairs, mixtures of diasteromers, mistures of diasteromeric pairs, mixtures of diasteromers in which one diastereomer is enriched relative to the other diastereomer(s) and mixtures of diasteromeric pairs in which one diastereomeric pair is enriched relative to the other diastereomeric pair(s).
  • the mixture is enriched in one diastereomer or diastereomeric pair(s) relative to the other diastereomers or diastereomeric pair(s), the mixture is enriched with the depicted or referenced diastereomer or diastereomeric pair(s) relative to other diastereomers or diastereomeric pair(s) for the compound, for example, by a molar excess of at least 50%, 75%, 90%, 95% 99% or 99.5%.
  • the diastereoisomeric pairs may be separated by methods known to those skilled in the art, for example chromatography or crystallization and the individual enantiomers within each pair may be separated as described above.
  • Example 1 Specific procedures for chromatographically separating diastereomeric pairs of precursors used in the preparation of compounds disclosed herein are provided in Example 1.
  • compounds of the present invention may associated in isolated form with solvent or water, as in a "solvate” or “hydrate”.
  • References to the disclosed compounds or structural formulas depicting the disclosed compounds are meant to include such solvates and hydrates.
  • the disclosed compounds, pharmaceutical compositions and methods can be used to inhibit CCR8 activity, to inhibit 1-309 activity and to inhibit or treat
  • CCR8 and/or 1-309 conditions mediated by CCR8 and/or 1-309, including inflammatory disorders and allergic conditions.
  • the disclosed compounds can also be advantageously used to inhibit conditions mediated by esinophils and monocytes, T lymphocytes and other immune system cells which express CCR8, including inflammatory disorders and allergic mediated by these cells.
  • allergic conditions for which the disclosed compounds, pharmaceutical compositions and methods are particularly effective include asthma.
  • Other allergic conditions which are expected to be treatable by inhibiting CCR8 activity include, atopic dermatitis, allergic rhinitis, systemic anaphylaxis or hypersensitivity responses, drug allergies (e.g., to penicillin, cephalosporins), insect sting allergies and dermatoses such as dermatitis, eczema, atopic dermatitis, allergic contact dermatitis and urticaria.
  • diseases with an inflammatory component for which the disclosed compounds, pharmaceutical composition and methods are effective include rheumatoid arthritis, osteoarthritis, inflammatory bowel disease [e.g., such as ulcerative colitis, Crohn's disease, ileitis, Celiac disease, nontropical Sprue, enteritis, enteropathy associated with seronegative arthropathies, microscopic or collagenous colitis, eosinophilic gastroenteritis, or pouchitis resulting after proctocolectomy, and ileoanal anastomosis] and disorders of the skin [e.g., psoriasis, erythema, pruritis, and acne].
  • inflammatory bowel disease e.g., such as ulcerative colitis, Crohn's disease, ileitis, Celiac disease, nontropical Sprue, enteritis, enteropathy associated with seronegative arthropathies, microscopic or collagenous colitis, eosinophilic gastroenteritis, or
  • autoimmune diseases also have an inflammatory component.
  • examples include multiple sclerosis, systemic lupus erythematosus, myasthenia gravis, juvenile onset diabetes, glomerulonephritis and other nephritides, autoimmune thyroiditis, Behcet's disease and graft rejection (including allograft rejection or graft-versus-host disease).
  • the inflammatory component of these disorders is believed to be mediated, at least in part, by CCR8.
  • Diseases characterized by repurfusion have an inflammatory component that is believed to be mediated, at least in part by CCR8. Examples include stroke, cardiac ischemia, and the like. The disclosed compounds and compositions also can be used to treat these disorders.
  • CCR8 diseases and conditions with an inflammatory component believed to be mediated by CCR8 include mastitis (mammary gland), vaginitis, cholecystitis, cholangitis or pericholangitis (bile duct and surrounding tissue of the liver), chronic bronchitis, chronic sinusitis, chronic inflammatory diseases of the lung which result in interstitial fibrosis, such as interstitial lung diseases (ILD) (e.g., idiopathic pulmonary fibrosis, or ILD associated with rheumatoid arthritis, or other autoimmune conditions), hypersensitivity pneumonitis, collagen diseases and sarcoidosis.
  • ILD interstitial lung diseases
  • vasculitis e.g., necrotizing, cutaneous, and hypersensitivity vasculitis
  • spondyloarthropathies e.g., spondyloarthropathies
  • scleroderma e.g., atherosclerosis
  • restenosis e.g., restenosis
  • myositis including polymyositis, dermatomyositis
  • pancreatitis e.g., pancreatitis and insulin-dependent diabetes mellitus.
  • CCR8 including one of the aforementioned diseases or conditions, is said “to be in need of CCR8 inhibition".
  • the subject with a disease or condition of this type is "treated” when at least one of the symptoms associated with the disease or condition is alleviated (therapeutic treatment) or inhibited or prevented (prophylactic treatment), in whole or in part.
  • a "subject” is a mammal, preferably a human, but can also be an animal in need of veterinary treatment, e.g., companion animals (e.g., dogs, cats, and the like), farm animals (e.g., cows, sheep, pigs, horses, and the like) and laboratory animals (e.g., rats, mice, guinea pigs, and the like).
  • companion animals e.g., dogs, cats, and the like
  • farm animals e.g., cows, sheep, pigs, horses, and the like
  • laboratory animals e.g., rats, mice, guinea pigs, and the like.
  • a "subject in need of CCR8 inhibition” is a subject in whom a beneficial therapeutic or prophylactic effect can be achieved by inhibiting CCR8 function or activity.
  • an "effective amount" of the disclosed CCR8 inhibitors is the quantity which inhibits CCR8 activity in a subject in need of such inhibition, or which, when administered to a subject with a CCR8 mediated disease, ameliorates the symptoms of the disease or condition, delays the onset of the symptoms and/or increases longevity.
  • the precise amount of CCR8 inhibitor administered to the subject will depend on the type and severity of the disease or condition and on the characteristics of the subject, such as general health, age, sex, body weight and tolerance to drugs.
  • the dosage may also vary according to the route of administration, which includes oral, aerosol, rectal, transdermal, subcutaneous, intravenous, intramuscular, intraperitoneal and intranasal.
  • An "effective amount” typically ranges between about 0.01 mg/kg/day to about 100 mg/kg/day, preferably between about 0.5 mg/kg/day to about 50 mg/kg/day.
  • the CCR8 inhibitors described herein, and the pharmaceutically acceptable salts thereof can be used in pharmaceutical preparations in combination with a pharmaceutically acceptable carrier or diluent.
  • suitable pharmaceutically acceptable carriers include inert solid fillers or diluents and sterile aqueous or organic solutions.
  • the CRTH2 inhibitor will be present in such pharmaceutical compositions in amounts sufficient to provide the desired dosage amount in the range described herein. Techniques for formulation and administration of the compounds of the instant invention can be found in Remington: the Science and Practice of Pharmacy, 19 th edition, Mack Publishing Co., Easton, PA (1995).
  • the CCR8 inhibitor or salts thereof can be combined with a suitable solid or liquid carrier or diluent to form capsules, tablets, pills, powders, syrups, solutions, suspensions and the like.
  • the tablets, pills, capsules, and the like contain from about 1 to about 99 weight percent of the active ingredient and a binder such as gum tragacanth, acacias, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid, a lubricant such as magnesium stearate; and a sweetening agent such as sucrose lactose or saccharin.
  • a dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as a fatty oil.
  • tablets may be coated with shellac, sugar or both.
  • a syrup or elixir may contain, in addition to the active ingredient, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and a flavoring such as cherry or orange flavor.
  • the disclosed CCR8 inhibitor, or salts thereof can be combined with sterile aqueous or organic media to form injectable solutions or suspensions.
  • aqueous or organic media for example, solutions in sesame or peanut oil, aqueous propylene glycol and the like can be used, as well as aqueous solutions of water-soluble pharmaceutically-acceptable salts of the compounds.
  • Dispersions can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
  • the compounds may also be formulated as a depot preparation.
  • Such long acting formulations may be administered by implantation, for example, subcutaneously or intramuscularly or by intramuscular injection.
  • implantation for example, subcutaneously or intramuscularly or by intramuscular injection.
  • sparingly soluble derivatives for example, as sparingly soluble salts.
  • a terminal methyl group in a compound described herein can be shown as a straight line with or without "CH3" on its terminus:
  • the present invention is directed to a compound represented by any one of Structural Formulas (I)-(XVI) (and methods of use thereof), provided that when R 1 is a substituted aromatic group, then the aromatic group represented by R 1 is substituted with a group other than pyrazole; provided that when X is O and R 4 is an aliphatic group, then the aliphatic group represented by R 4 is substituted with a group other than -COOR x ; and provided that when R 4 is a substituted phenyl, substituted benzyl or substituted phenethyl group, then the phenyl, benzyl or phenethyl group represented by R 4 is substituted with a group other than -NO 2 , -NR X R X , -CONR x R x , -NR x COR x , or an aliphatic group substituted with -NO 2 , -NR X R X , -CONR x
  • Each R x is independently H, an aliphatic group, a substituted aliphatic group, an aryl group, a substituted aryl group, a non-aromatic ring or a substituted non-aromatic ring.
  • the subject matter encompassed by Structural Formulas (I)-(III) excludes N-[4-[[(4-methoxyphenyl)amino]sulfonyl]-l-naphthalenyl]- benzamide, N-[4-[(2-propenylamino)sulfonyl]-l-naphthalenyl]-benzamide, N-[4-(4- morpholinylsulfonyi)- 1 -naphthalenyl] -benzamide or N-[4-( 1 -piperidinylsulfonyl)- 1 -naphthalenyl] -benzamide.
  • LC/MS spectra were obtained using a MicroMass Platform LC (Phenomenx C18 column, 5 micron, 50 x 4.6 mm) equipped with a Gilson 215 Liquid Handler. Standard LC/MS conditions are as follows: Formic acid-Standard conditions:
  • N-[4-(3-Methoxy-phenylsulfamoyl)-naphthalen-l-yl]-benzamide (A-l) To a solution of 4-benzoylamino-naphthalene-l -sulfonyl chloride (320 mg, 0.93 mmol) in CH 2 C1 2 (20 mL) was added triethylamine (0.26 mL, 1.85 mmol) and m- anisidine (137 mg, 1.11 mmol). The resultant solution was stirred at 25 °C overnight. The reaction mixture was quenched with water and extracted with CH 2 C1 2 .
  • N-(4-PhenyIsulfamoyl-naphthalen-l-yI)-benzamide (A-7) The title compound was made following the general procedure in Scheme 2, substituting aniline for administrat-anisidine. ! H ⁇ MR (300MHz, MeOD) ⁇ 8.76 (d, IH), 8.16 (d, IH), 8.05 (d, IH), 7.96 (d, 2H), 7.60 (m, 6H), 7.00 (m, 5H), LC/MS m/z 403 (M + H) + .
  • A-47 and A-48 were obtained.
  • A- 49 1H ⁇ MR (300 MHz, CDC1 3 ) ⁇ 8.42 (d, IH), 8.18 (s, IH), 8.00 (d, 2H), 7.65 (d, IH), 7.30 (m, 3H), 7.05 (t, IH), 6.95 (m, 8H), 5.30 (s, br, IH), 3.50 (s, br, IH), 3.20 (q, 2H), 3.08 (s, IH), 2.21 (s, 3H), 2.05 (m, 3H), 1.20 (m, 3H), 0.60 (m, 2H), 0.05 (t, 3H); LC/MS m/z 542 (M + H) + ;
  • 4-(4-Benzoylamino-naphthalene- 1 -sulfonylamino)-piperidine- 1 -carboxylic acid tert- butyl ester (11) was prepared following the general procedure in Scheme 2. To a solution of 4-(4-benzoylamino-naphthalene- 1 -sulfonylamino)-piperidine- 1 - carboxylic acid tert-butyl ester (11) in MeOH was added a solution of 4 ⁇ HC1 in dioxane. The reaction mixture was stirred at 25 °C for 5 h and then concentrated in vacuo. The crude material was purified by reverse phase HPLC to provide the title compound.
  • N- ⁇ 4- [ 1 -(2-Bromo-acetyl)-3 -c/s-methyl-pi ⁇ eridin-4-ylsulfamoyl] -naphthalen- 1 -yl ⁇ - 2-methyl-benzamide (100 mg, 0.18 mM) was dissolved in a mixture of acetonitrile (1 mL) and water (0.25 mL). Potassium carbonate (37 mg, 0.27 mmol) was added followed by piperazine-1 -carboxylic acid tert-butyl ester (37 mg, 0.2 mM). The reaction was stirred for 1 hour at room temperature before being passed through a plug of silica gel.
  • the title compound was prepared from A-21 according to the general procedure in Scheme 7. To a solution of A-21 in ethyl acetate was added Pd(OH) 2 and butyric anhydride (1.0 eq). The vessel was evacuated and pressurized to 50 psi H 2 and allowed to agitate on a Parr apparatus overnight. The solution was filtered through a celite plug, washed with hot ethyl acetate and concentrated at 40°C at reduced pressure. The residue was purified using flash chromatography to provide the title compound.
  • 4-(4-Amino-naphthalene- 1 -sulfonylamino)-piperidine- 1 -carboxylic acid tert-butyl ester (20) was prepared according to the general procedure in Scheme 3 substituting 4-[4-(l,3-dioxo-l,3-dihydro-isoindol-2-yl)-naphthalene-l-sulfonylamino]- piperidine-1 -carboxylic acid tert-butyl ester for 4-(l,3-dioxo-l,3-dihydro-isoindol-2- yl)-naphthalene-l-sulfonic acid (4-methoxyphenyl)-amide.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des inhibiteurs du CCR8 représentés par les formules développées (I), dont les variables sont traitées dans le descriptif. L'invention concerne également des procédés de traitement d'un patient présentant un état médié par CCR8, notamment l'asthme, par administration de l'un de ces inhibiteurs du CCR8.
EP03808569A 2002-12-23 2003-12-23 Inhibiteurs du ccr8 Withdrawn EP1590327A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43653702P 2002-12-23 2002-12-23
US436537P 2002-12-23
PCT/US2003/041360 WO2004058709A1 (fr) 2002-12-23 2003-12-23 Inhibiteurs du ccr8

Publications (1)

Publication Number Publication Date
EP1590327A1 true EP1590327A1 (fr) 2005-11-02

Family

ID=32682404

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03808569A Withdrawn EP1590327A1 (fr) 2002-12-23 2003-12-23 Inhibiteurs du ccr8

Country Status (4)

Country Link
US (1) US7378525B2 (fr)
EP (1) EP1590327A1 (fr)
AU (1) AU2003303483A1 (fr)
WO (1) WO2004058709A1 (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE502928T1 (de) 2000-11-01 2011-04-15 Millennium Pharm Inc Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung
US7491827B2 (en) * 2002-12-23 2009-02-17 Millennium Pharmaceuticals, Inc. Aryl sulfonamides useful as inhibitors of chemokine receptor activity
CA2545644C (fr) * 2003-11-12 2011-11-01 Lg Life Sciences Ltd. Agonistes du recepteur de la melanocortine
US20060045953A1 (en) * 2004-08-06 2006-03-02 Catherine Tachdjian Aromatic amides and ureas and their uses as sweet and/or umami flavor modifiers, tastants and taste enhancers
TW200630337A (en) 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
BRPI0519585A2 (pt) * 2004-12-20 2009-02-25 Hoffmann La Roche compostos de fàrmula i; processo para a fabricaÇço de compostos de fàrmula i; composiÇÕes farmacÊuticas; mÉtodo para o tratamento e/ou profilaxia de doenÇas que estço associadas com a dpp-iv e usos destes compostos
EP1724269A1 (fr) * 2005-05-20 2006-11-22 Sanofi-Aventis Deutschland GmbH Dérivés des amides hétéroarylcarboxyliques-sulfamoylalkylamides comme inhibiteurs du facteur Xa
US9296697B2 (en) 2005-08-24 2016-03-29 Abbott Laboratories Hetaryl-substituted guanidine compounds and use thereof as binding partners for 5-HT5-receptors
WO2007110449A1 (fr) 2006-03-29 2007-10-04 Euro-Celtique S.A. Composés de benzènesulfonamide et utilisation de ceux-ci
US8791264B2 (en) 2006-04-13 2014-07-29 Purdue Pharma L.P. Benzenesulfonamide compounds and their use as blockers of calcium channels
TW200812963A (en) 2006-04-13 2008-03-16 Euro Celtique Sa Benzenesulfonamide compounds and the use thereof
CN101563075B (zh) * 2006-12-26 2011-09-28 大鹏药品工业株式会社 糖尿病性神经病治疗剂
WO2008099165A1 (fr) * 2007-02-15 2008-08-21 Astrazeneca Ab Dérivés de pipéridine et leur utilisation pour le traitement de maladies à médiation par ccr8
WO2008124118A1 (fr) 2007-04-09 2008-10-16 Purdue Pharma L.P. Composés benzènesulfonylés et leur utilisation
US8765736B2 (en) 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
CN103384668B (zh) 2010-09-03 2017-05-31 福马Tm有限责任公司 用于抑制nampt的化合物和组合物
EA026368B1 (ru) 2011-12-21 2017-03-31 Новира Терапьютикс, Инк. Противовирусные агенты против гепатита в
AU2013307337B2 (en) 2012-08-28 2018-07-19 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of Hepatitis B
CN105189453B (zh) 2013-02-28 2018-04-10 爱尔兰詹森科学公司 氨磺酰基‑芳基酰胺及其作为用于乙型肝炎治疗的药物的用途
WO2014165128A2 (fr) 2013-03-12 2014-10-09 Novira Therapeutics, Inc. Agents antiviraux contre l'hépatite b
WO2014161888A1 (fr) 2013-04-03 2014-10-09 Janssen R&D Ireland Dérivés de n-phénylcarboxamide et leur utilisation comme médicaments pour le traitement de l'hépatite b
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
CA2935719C (fr) 2013-07-25 2021-11-02 Janssen Sciences Ireland Uc Derives de pyrrolamide a substitution glyoxamide et leur utilisation en tant que medicaments pour le traitement de l'hepatite b
AU2014338947B2 (en) 2013-10-23 2018-02-22 Janssen Sciences Ireland Uc Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9181288B2 (en) 2014-01-16 2015-11-10 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
KR20160128305A (ko) 2014-02-05 2016-11-07 노비라 테라퓨틱스, 인코포레이티드 Hbv 감염의 치료를 위한 병용 요법
JP6495929B2 (ja) 2014-02-06 2019-04-03 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー スルファモイルピロールアミド誘導体およびｂ型肝炎の治療のための医薬としてのその使用
US9400280B2 (en) 2014-03-27 2016-07-26 Novira Therapeutics, Inc. Piperidine derivatives and methods of treating hepatitis B infections
AU2016232801A1 (en) 2015-03-19 2017-10-12 Novira Therapeutics, Inc. Azocane and azonane derivatives and methods of treating hepatitis B infections
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
TW201718496A (zh) 2015-09-29 2017-06-01 諾維拉治療公司 B型肝炎抗病毒劑之晶型
BR112018071048A2 (pt) 2016-04-15 2019-05-07 Janssen Sciences Ireland Uc combinações e métodos que compreendem um inibidor da montagem de capsídeos
KR102037494B1 (ko) 2017-12-11 2019-10-28 씨제이헬스케어 주식회사 광학활성을 갖는 피페리딘 유도체의 중간체 및 이의 제조방법
MA52019A (fr) 2018-03-14 2021-01-20 Janssen Sciences Ireland Unlimited Co Schéma posologique de modulateur d'assemblage de capside
CA3127152A1 (fr) 2019-02-22 2020-08-27 Janssen Sciences Ireland Unlimited Company Derives d'amide utiles dans le traitement d'une infection par le virus de l'hepatite b ou de maladies induites par le virus de l'hepatite b
US11491148B2 (en) 2019-05-06 2022-11-08 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases
KR20190120112A (ko) 2019-10-08 2019-10-23 씨제이헬스케어 주식회사 광학활성을 갖는 피페리딘 유도체의 중간체 및 이의 제조방법
GB201919212D0 (en) * 2019-12-23 2020-02-05 Ucb Biopharma Sprl Dihydro-cyclopenta-isoquinoline sulfonamides derivatives
GB201919216D0 (en) * 2019-12-23 2020-02-05 UCB Biopharma SRL Tetrahydrobenzo-quinoline sulfonamides derivative compounds
GB201919210D0 (en) * 2019-12-23 2020-02-05 UCB Biopharma SRL Dihydro-cyclopenta-isoquinoline derivatives
GB201919214D0 (en) * 2019-12-23 2020-02-05 Ucb Biopharma Sprl Tetrahydrobenzo-quinoline sulfonamide derivatives useful as IGE modulators
GB201919213D0 (en) * 2019-12-23 2020-02-05 Ucb Biopharma Sprl Dihydrocyclopenta-Isoquinoline-Sulfanamide derivatives compounds
EP4175949A4 (fr) * 2020-07-03 2024-02-28 Nanjing Immunophage Biotech Co., Ltd. Méthodes et compositions pour cibler des treg au moyen d'inhibiteurs de ccr8
AR131211A1 (es) 2022-11-30 2025-02-26 Idorsia Pharmaceuticals Ltd Derivados de aril- y heteroaril-sulfonamida como moduladores de ccr8
WO2024133292A1 (fr) * 2022-12-19 2024-06-27 Katholieke Universiteit Leuven Nouveaux antagonistes de ccr8
CN120271495B (zh) * 2025-06-12 2025-09-19 成都道合尔医药技术有限公司 一种(3r,4r)-n-pg-4-氨基-3-甲基哌啶的合成方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE858551C (de) 1951-01-23 1952-12-08 Cassella Farbwerke Mainkur Ag Verfahren zur Herstellung von Piperidinderivaten
JP2528451B2 (ja) 1986-07-09 1996-08-28 北陸製薬株式会社 ナフタレンスルホンアミド誘導体
JPH07122740B2 (ja) 1987-02-25 1995-12-25 富士写真フイルム株式会社 ハロゲン化銀カラ−写真感光材料
WO1991012237A1 (fr) 1990-02-08 1991-08-22 Eisai Co., Ltd. Derive de sulfonamide de benzene
RU2051146C1 (ru) 1991-06-28 1995-12-27 Институт молекулярной генетики РАН 5-замещенные нафталин-1-сульфониламиды и способ их получения
RU2051147C1 (ru) 1991-06-28 1995-12-27 Институт молекулярной генетики РАН 5-замещенные нафталин-1-(диметилен)-сульфониламиды и способ их получения
RU2053226C1 (ru) 1991-06-28 1996-01-27 Институт молекулярной генетики РАН 5-аминонафталин-1-замещенные (алкоксиэтил)сульфониламиды и способ получения 5-аминонафталин-1-замещенных (алкоксиэтил)сульфониламидов
DE4133514A1 (de) * 1991-10-10 1993-04-15 Basf Ag Sulfonamide, die sich von 1-hydroxy-6-aminonaphthalin-3-sulfonsaeure (i-saeure) ableiten
US5378715A (en) 1992-02-24 1995-01-03 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
US5571898A (en) * 1992-10-19 1996-11-05 Basf Aktiengesellschaft Basic dyes based on amides of j-acid (1-hydroxy-6-aminonaphthalene-3-sulfonic acid) and amides of j-acid
EP0618223A3 (fr) 1993-03-08 1996-06-12 Sandoz Ltd Peptides inhibent la libération d'interleukine 1-bêta utiles comme agents antiinflammatoires.
GB9504854D0 (en) 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
TW402606B (en) 1994-09-02 2000-08-21 Dev Center Biotechnology New fluorogenic substrates for assay of angiotensin converting enzyme
US5707985A (en) * 1995-06-07 1998-01-13 Tanabe Seiyaku Co. Ltd. Naphthyl-, quinolyl- and isoquinolyl- sulfonamide derivatives as cell adhesion modulators
WO1997020822A1 (fr) 1995-12-01 1997-06-12 Novartis Ag Quinazolin-2,4-diazirines en tant qu'antagoniste du recepteur du neuropeptide y
US5994398A (en) * 1996-12-11 1999-11-30 Elan Pharmaceuticals, Inc. Arylsulfonamides as phospholipase A2 inhibitors
PT966436E (pt) 1997-02-21 2003-03-31 Bayer Ag Arilsulfonamidas e analogos e sua aplicacao para o tratamento de doencas neurodegenerativas
DE19754490A1 (de) 1997-12-09 1999-06-10 Boehringer Ingelheim Pharma Durch einen Aminocarbonylrest substituierte Bicyclen, ihre Herstellung und ihre Verwendung als Arzneimittel
EE200000432A (et) 1998-01-23 2001-12-17 Bayer Aktiengesellschaft Naftüül- ja aniliidasendatud sulfoonamiidid
US6506747B1 (en) 1998-06-05 2003-01-14 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents
DE19912638A1 (de) 1999-03-20 2000-09-21 Bayer Ag Naphthylcarbonsäureamid-substituierte Sulfonamide
DE19934321A1 (de) 1999-07-21 2001-01-25 Bayer Ag Naphthyl-substituierte Sulfonamide
DE10000739A1 (de) 2000-01-11 2001-07-12 Merck Patent Gmbh Piperidin- und Piperazinderivate
WO2001058484A2 (fr) 2000-02-10 2001-08-16 Schering Corporation Nouvelles utilisations des recepteurs ccr8 de mammiferes et reactifs associes
DE10053796A1 (de) 2000-10-30 2002-05-08 Bayer Ag Verwendung von Naphthalinsulfonamiden
EP1377549A1 (fr) 2001-03-12 2004-01-07 Millennium Pharmaceuticals, Inc. Heterocycles fonctionnalises en tant que modulateurs de la fonction du recepteur de chimiokines et procedes de mise en oeuvre
US7491827B2 (en) 2002-12-23 2009-02-17 Millennium Pharmaceuticals, Inc. Aryl sulfonamides useful as inhibitors of chemokine receptor activity
EP1869046A1 (fr) 2005-04-04 2007-12-26 AstraZeneca AB Nouveaux diazaspiroalcanes et leur application au traitement de maladies faisant intervenir ccr8
JP2008534679A (ja) 2005-04-04 2008-08-28 アストラゼネカ・アクチエボラーグ 新規ジアザスピロアルカン類およびｃｃｒ８介在疾患の処置のためのそれらの使用
EP1869044A1 (fr) 2005-04-04 2007-12-26 AstraZeneca AB Nouveaux diazaspiroalcanes et leur application au traitement de maladies faisant intervenir ccr8
TW200800999A (en) 2005-09-06 2008-01-01 Astrazeneca Ab Novel compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2004058709A1 *

Also Published As

Publication number Publication date
WO2004058709A1 (fr) 2004-07-15
US7378525B2 (en) 2008-05-27
US20040209948A1 (en) 2004-10-21
AU2003303483A1 (en) 2004-07-22

Similar Documents

Publication Publication Date Title
US7378525B2 (en) CCR8 inhibitors
US7329755B2 (en) CCR8 inhibitors
US8063222B2 (en) Aryl sulfonamides useful as inhibitors of chemokine receptor activity
US6451797B1 (en) Muscarinic antagonists
AU701452B2 (en) Benzylpiperidines and piperazines as muscarinic antagonists
EP1343760B1 (fr) Antagonistes muscariniques
DE60209736T2 (de) Piperidinverbindungen, die sich als modulatoren der chemokinrezeptoraktivität eignen
EP1444203A1 (fr) Ligands du recepteur des cannabinoides
EP1091956B1 (fr) Antagonistes de muscarine
EP1611090A2 (fr) Ligands de recepteurs de cannabinoides
CA2123728A1 (fr) Derives de l'uree et leur utilisation comme inhibiteurs de l'acat
EP0661266A1 (fr) Composés cycliques aminés substitués comme 5HT2 antagonistes
KR20140107551A (ko) RORc 조절제로서의 벤질 설폰아마이드 유도체
EP1180513A1 (fr) Composes d'amides cycliques, leurs procedes de preparation et d'utilisation
CA2259655C (fr) Piperidines 1,4-disubstituees a titre d'antagonistes muscariniques
KR20060095865A (ko) 글리신 수송 억제제로서의 비시클릭 [3.1.0] 유도체
SK142399A3 (en) Indazole amide compounds as serotoninergic agents
MXPA02003136A (es) Antagonistas muscarinicos.
EP1448566B1 (fr) Antagonistes des recepteurs de la chimiokine et methodes d'utilisation de ces antagonistes
JP3510324B2 (ja) 尿素誘導体
JP3836892B2 (ja) 置換環状アミン化合物、その製造法及びそれを含有する循環器官用剤
MXPA01000106A (es) Antagonistas muscarinicos
HK1063789B (en) Chemokine receptor antagonists and methods of use thereof
JPWO2000066551A1 (ja) 環状アミド化合物、その製造法および用途
AU2002346366A1 (en) Cannabinoid receptor ligands

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050725

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

17Q First examination report despatched

Effective date: 20061215

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070426